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On behalf of the Editorial Board of Nuclear Receptor
Research, it is a great pleasure to welcome you to the
inaugural issue of the journal.We are proud to introduce the
ﬁrst thematic issue of many to come.
The fact that virtually every single aspect of cell function
and the complex network of regulatory processes in an
organism involve crucial roles by nuclear receptors is not
surprising at the present time. Accordingly, thousands of
studies are published every year in hundreds of journals with
very broad spectra, making it diﬃcult for researchers in the
ﬁeld to ﬁnd speciﬁc information of interest to them. This
is the reason why Nuclear Receptor Research was born; to
gather in one journal most of the advances covering all facets
of this cardinal group of regulatory transcription factors.
Thus, Nuclear Receptor Research is intended to meet a
crucial need of researchers in an ever expanding and exciting
ﬁeld that has shown an extraordinary progress since the late
1800s.
Historical Events: Perhaps the ﬁrst steps in the discovery
of nuclear receptors may be traced to 1889, when the French
physiologist Charles Édouard Brown-Séquard suggested to
the Society of Biology in Paris that the testes might pro-
duce an active and invigorating substance able to act in
the whole body, and proposed that it could be obtained
from animals and injected into men, rejuvenating them.
Actually, he assayed that “testicular liquid” by injecting
himself and experiencing radical changes such as regaining
his lost strength and natural impetuosity [1]. In 1902, the
English physiologists William Bayliss and Ernest Starling
discovered the ﬁrst biological regulator produced by one
tissue and conveyed by the bloodstream to another to eﬀect
physiological activity. They isolated the ﬁrst postman that
delivered biological messages, the secretin [2]. Three years
later, Starling coined the name hormone [3] of this type of
compounds, a word derived from the Greek meaning ‘to
arouse or excite’. He deﬁned it as “the chemical messengers
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which speeding from cell to cell along the blood stream,
may coordinate the activities and growth of diﬀerent parts
of the body”. Thus, the concept that hormonal regulation as a
major biological event was ﬁrst proposed in this sentence and
early physiology took a major step forward. Some years later,
Edward Kendall at the Mayo Clinic isolated an iodoamino
acid, thyroxine, and also puriﬁed the compound E from the
adrenal gland, which was used to treat rheumatoid arthritis
and was renamed cortisone [4].
In 1958, Elwood Jensen synthesized a radioactive estrogen
in the Fermi laboratory at the University of Chicago and
administered it to ovariectomized rats. The hormone was
retained in the uterus and other reproductive tissues; organs
that grow in response to estrogen [5], and thus the steroid
receptor theory was born. Such organ-speciﬁc retention
of estradiol was arguably the ﬁrst evidence for binding
of a hormone to a receptor, yet even as late as 1968,
some pharmacologists felt the use of the word “receptor”,
to describe the estradiol-binding entity, was inappropriate
[6].
The ﬁrst cloning of a nuclear receptor was achieved
in 1985 [7], a development that led to the birth of a
superfamily of ligand activated transcription factors; the
nuclear receptor superfamily. Another term was also born at
the same time, “orphan receptors”. Unlike those members
that had previously been identiﬁed with prior knowledge
of a naturally occurring ligand, “orphan receptors” share
sequence homology and structural similarity with the classic
group of ligand-activated transcription factors, but their
putative endogenous ligand(s) remained unknown.
To date, nuclear receptors constitute the largest group
of transcription factors in animals comprising 48 family
members in humans and 270 in Caenorhabditis elegans [8].
The study of how these receptors interact with genomic
regions to control a plethora of biological processes has
provided critical insight into physiology, signaling pathways,
cell cycle, diﬀerentiation, development, evolution, and the
molecular basis of most diseases. In view of these facts
and the evident widespread relevance of the superfamily,
their roles in the etiology of several human diseases have
transformed these receptors into attractive therapeutic targets
for the design and development of novel speciﬁc drug
treatments.
The elucidation of the crystal structure of the nuclear
receptor Ligand Binding Domain revealed various confor-
mations and structure conservation among many members of
this superfamily [9]. Moreover, the advent of structural biol-
ogy combined with new technologies like high-throughput
methods, novel biochemical methods, and pathway analysis
tools have led to new discoveries of diﬀerent ligand binding
sites, allowing the elucidation of speciﬁc molecular mech-
anisms of activation of nuclear receptors and increasing the
pharmacological eﬃcacies of new drugs. Following this line,
new molecules which modulate nuclear receptors have been
discovered, making this family of receptors one of the top
ten drug targets accounting for 13% of FDA approved drugs
[10, 11].
Early contribution to the ﬁeld from Latin America:
Latin American scientists have made important contributions
to the ﬁeld of nuclear receptor research. The Argentinean
Bernardo Houssay is one of the major contributors and
ﬁrst Nobel laureate in sciences in the region due to his
discoveries on the role of the anterior hypophysis gland in
carbohydrate metabolism. In the 1930s, Dr. Houssay showed
the diabetogenic eﬀect of anterior hypophysis extracts and
the decrease in diabetes severity with anterior hypophysec-
tomy, leading to other key discoveries such as the pituitary-
adrenocortical relationship. These discoveries stimulated the
study of hormonal feedback control mechanisms which are
central to all aspects of modern endocrinology and hormone-
receptor interaction. Latin America is also credited with a
number of professors and institutions awarded prestigious
prizes and fellowships from philanthropic institutions, like
the John S. Guggenheim Foundation, the Howard Hughes
Medical Institute, and the PewCharitable Trusts, to name just
a few. As economies of the continent improve, governments
are devoting greater resources to research, as well as pro-
viding better infrastructure and policies to support science.
Therefore, this inaugural issue was focused on some of the
most recent contributions of Latin American researchers in
the ﬁeld.
Content of this issue: In this thematic issue of Nuclear
Receptor Research, there is a collection of excellent review
and research articles contributed by researchers in Latin
America.
The paper by Thaís Soares Farnesi-de-Assunção et al.
evaluates the eﬀects of the PPAR𝛾 endogenous ligand
15-deoxy-Δ12,14-PGJ2 (15d-PGJ2) on the inﬂammatory
response of dendritic cells. Usually, PPAR𝛾 ligands nega-
tively regulate the innate and adaptative immune response
in diﬀerent experimental models. Although several studies
have shown an anti-inﬂammatory action for 15d-PGJ2, a
few reports have focused on the potential mechanism of
its direct action on dendritic cells. Therefore, the authors
have evaluated the expression of surface molecules such as
MHC-II, CD80 and CD86 and have also compared cytokine
production in cells treated with 15-d-PGJ2 or rosiglitazone.
The natural ligand 15d-PGJ2 shows as a more eﬃcient agent
to reduce both the expression of CD80 and CD86 (without
aﬀecting the expression of MCH-class II) and the production
of the proinﬂammatory cytokines IL-12, IFN-γ, and TNF-α.
Because PPAR𝛾 is an attractive pharmacologic target where
dendritic cells are involved, it is suggested that this natural
PPAR𝛾 ligand could be a therapeutic strategy in disease
to reduce the expression of costimulatory molecules and
modulate the inﬂammatory response.
Gisela Mazaira et al. evaluate a novel model for the
mechanism of action of steroid receptors. For several years,
it was thought that receptor traﬃcking throughout the
cytoplasm was a stochastic and passive mechanism triggered
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by the dissociation of the Hsp90-based molecular complex
from the receptor upon ligand binding. Here, is discussed
the experimental evidence that has led to assign a key role
to Hsp90-binding immunophilins in the regulation of this
process, demonstrating that the Hsp90-based heterocomplex
is indeed an essential component for receptor movement.
Roles of Hsp90-binding immunophilins in the nuclear
translocation of steroid receptors through the nuclear pore,
how transcriptional activity is aﬀected, and the consequence
in cancer development are also discussed.
Judith Toneatto et al. have analyzed the relevance of
molecular chaperones and co-chaperones in the process
of adipocyte diﬀerentiation modulated by both the gluco-
corticoid receptor and the mineralocorticoid receptor. The
potential coordinated action of glucocorticoids and miner-
alocorticoids in adipose tissue is evaluated in an attempt to
understand the molecular basis of obesity and the metabolic
syndrome. The roles of steroid metabolizing enzymes,
adipocytes as a source of aldosterone, and the recently
discovered inﬂuence of the FK506-binding immunophilin of
51-kDa are examined in detail.
Ana Liberman et al. dissect several aspects of the post-
translational regulation of the glucocorticoid receptor in
response to external stimuli. The pleiotropic actions of the
glucocorticoid receptor depends on the diﬀerent responsive
sequences in diﬀerent cell types, the multiple receptor
isoforms generated by alternative splicing and translation
initiation, the type of associated chaperones, and post-
translational modiﬁcations. In this article, post-translational
events on the receptor as well as associated proteins are ana-
lyzed. Events including actions of various protein-kinases,
acetylation, ubiquitination, methyltion, sumoylation, etc., are
presented. Cross-talk between neuroendocrine responses and
immune system is also discussed.
The article by Juliana Fattory et al. evaluate and provide
nuances on the modern methodology required for investiga-
tions focused on interactions between DNA and the DNA
binding domain of nuclear receptors; an event which is
necessary to shed light on important roles of the participation
of these receptors in transcriptional mechanisms and in
speciﬁc genes networks. The article discusses advantages
and disadvantages of these methods, provides tools to
answer some speciﬁc questions, and helps the reader to
choose the most suitable methodology to study receptor-
DNA interactions according to the speciﬁc question that
researchers may wish to answer.
The article by Aliesha González-Arenas et al. studies the
eﬀects of ligand binding on the subcellular localization of
progesterone receptor in a grade III human astrocytoma cell
line, and have analyzed by microarray the proﬁle of expres-
sion of genes regulated by the natural agonist progesterone
(PR), the PR antagonist RU486, or both steroids. Inasmuch
as a direct relation between PR expression and astrocytoma
tumor grade exists, the authors focused their study on
the identiﬁcation of genes regulated by intracellular PR or
through other signaling pathways that inﬂuence astrocytomas
growth. Thirty genes were regulated by progesterone, forty-
one genes by RU486, and thirteen genes by the co-treatment
with both steroids. The genes that were modulated positively
or negatively after 12 h of treatment with steroid encode
for proteins involved in metabolism, transport, cell cycle,
proliferation, metastasis, apoptosis, processing of nucleic
acids and proteins, adhesion, pathogenesis, immunological
processes, cytoskeleton organization and membrane recep-
tors. This agrees with the fact that malignant astrocytomas
have a complex process in which the expression of various
genes is modiﬁed to allow the tumor cells to have oxygen
supply and nutrients, escape the immune system and have the
ability to migrate and invade.
Again, on behalf of all members of the Editorial Board of
this new born journal, you are very welcome to this inaugural
issue of Nuclear Receptor Research. We all look forward
to the academic dialogue and prosperous collaborations we
hope and wish to initiate with this challenging endeavor.
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